CROSSTALK THERAPEUTICS LTD

Active Sandwich

Research and experimental development on biotechnology

0 employees website.com
Research and experimental development on biotechnology
C

CROSSTALK THERAPEUTICS LTD

Research and experimental development on biotechnology

Founded 27 Jan 2021 Active Sandwich, United Kingdom 0 employees website.com
Research and experimental development on biotechnology
Accounts Submitted 30 Sept 2025 Next due 30 Sept 2026 4 months remaining
Confirmation Submitted 2 Feb 2026 Next due 11 Feb 2027 9 months remaining
Net assets £-439K £2M 2024 year on year
Total assets £61K £672K 2024 year on year
Total Liabilities £501K £3M 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

Innovation House Innovation Way Discovery Park Sandwich Kent CT13 9FF United Kingdom

Email

info@example.com

Website

www.example.com

Full company profile for CROSSTALK THERAPEUTICS LTD (13162770), an active company based in Sandwich, United Kingdom. Incorporated 27 Jan 2021. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2021–2024)

Cash in Bank

£16.66k

Decreased by £666.52k (-98%)

Net Assets

-£439.48k

Increased by £2.18M (+83%)

Total Liabilities

£500.78k

Decreased by £2.85M (-85%)

Turnover

N/A

Employees

N/A

Debt Ratio

817%

Increased by 360 (+79%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

4 Allotments 4,425,509 Shares £3.00m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
20 Jun 2024656,266£65.627£0
20 Jun 202437,946£3.795£0
20 Jun 202462,435£50k£0.804
20 Jun 20243,668,862£2.95m£0.804

Officers

Officers

3 active
Status
Jernej GodecDirectorAmericanUnited States4020 Jun 2024Active
Michael GladstoneDirectorAmericanUnited States3920 Jun 2024Active
Williams, Nicholas AlexanderDirectorBritishEngland4027 Jan 2021Active

Shareholders

Shareholders (5)

Tshaka Bio, Inc
100.0%
4,425,609
Charles Grummitt
0.0%
0

Persons with Significant Control

Persons with Significant Control (0)

0 Active 1 Ceased

Medicxi Iii Lp

Ceased 20 Jun 2024

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
2 Feb 2026Confirmation StatementConfirmation statement made on 28 Jan 2026 with no updates
30 Sept 2025AccountsAnnual accounts made up to 31 Dec 2024
13 Mar 2025OfficersChange to director Mr Nicholas Alexander Williams on 28 Jan 2025
12 Mar 2025Confirmation StatementConfirmation statement made on 28 Jan 2025 with updates
12 Mar 2025Persons With Significant ControlCessation of Medicxi Iii Lp as a person with significant control on 20 Jun 2024
2 Feb 2026 Confirmation Statement

Confirmation statement made on 28 Jan 2026 with no updates

30 Sept 2025 Accounts

Annual accounts made up to 31 Dec 2024

13 Mar 2025 Officers

Change to director Mr Nicholas Alexander Williams on 28 Jan 2025

12 Mar 2025 Confirmation Statement

Confirmation statement made on 28 Jan 2025 with updates

12 Mar 2025 Persons With Significant Control

Cessation of Medicxi Iii Lp as a person with significant control on 20 Jun 2024

Recent Activity

Latest Activity

Confirmation statement made on 28 Jan 2026 with no updates

3 months ago on 2 Feb 2026

Annual accounts made up to 31 Dec 2024

7 months ago on 30 Sept 2025

Change to director Mr Nicholas Alexander Williams on 28 Jan 2025

1 years ago on 13 Mar 2025

Confirmation statement made on 28 Jan 2025 with updates

1 years ago on 12 Mar 2025

Cessation of Medicxi Iii Lp as a person with significant control on 20 Jun 2024

1 years ago on 12 Mar 2025